Bausch + Lomb stock gets BL1243 update after FDA meeting

Published on 10/07/2026 at 03:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bausch + Lomb stock centers on BL1243, an oral dry AMD candidate whose clinical path gained clarity after October 6 FDA talks. Q2 revenue was USD 1.39 billion, up 9.1 percent year over year.

BLCO, CA0717051076, Illustration mit AI erstellt.

Bausch + Lomb stock centers on BL1243 after the company reported progress on its oral dry age-related macular degeneration treatment following a constructive FDA meeting on October 6, 2026. The development discussion clarified the clinical path for the investigational therapy, according to GuruFocus.

BL1243 moves toward clinical testing

Bausch + Lomb plans to initiate clinical trials for BL1243 in 2027, with the program aimed at earlier-stage dry AMD. The candidate, also known as tonabersat, would add an oral option to a treatment area where current care often relies on invasive approaches, according to the October 6 report.

The FDA meeting does not represent an approval or a clinical efficacy result. Its significance is operational: the company now has greater clarity on development requirements before the planned 2027 trial work.

Revenue reached USD 1.39 billion

The latest reported quarter provides a separate measure of execution. For the quarter ended June 30, 2026, Bausch + Lomb generated USD 1.39 billion in revenue, up 9.1 percent from USD 1.28 billion a year earlier, according to Markets Insider. That comparison places the pipeline update alongside a business that was still expanding sales in the second quarter.

The same report said Citi assigned Bausch + Lomb a Buy rating and a USD 21.00 price target on October 5, 2026. MarketBeat's October 6, 2026 page lists a Hold consensus from 15 analysts, with an average target of USD 19.15, a high target of USD 24.00 and a low target of USD 16.00, while its consensus data also show six Buy ratings, eight Holds and one Sell rating.

Stock stays below its yearly high

BLCO was last at USD 17.18 on the NYSE on October 6, 2026 at 4:00 p.m. ET, up USD 0.01 or 0.06 percent on the session. The stock's 52-week range was USD 13.77 to USD 18.92, putting the latest price USD 1.74 below the yearly high.

Market capitalization stood at USD 6.1 billion on October 6, 2026. For investors, the next hard checkpoint is whether the 2027 BL1243 plan develops into a clinical program while revenue growth continues into the third quarter.

October results date is set

Bausch + Lomb will release third-quarter 2026 financial results on October 28, 2026, before an 8:00 a.m. ET conference call, according to Bausch + Lomb. The event will give investors the next scheduled update on sales, profitability and the company's eye-health pipeline.